InvestorsHub Logo
Followers 11
Posts 546
Boards Moderated 0
Alias Born 08/18/2017

Re: None

Monday, 02/14/2022 9:21:21 AM

Monday, February 14, 2022 9:21:21 AM

Post# of 704565
“ First, we intend to strengthen our leadership in oncology broadly and leverage that position for sustained long-term success. We’ve done an excellent job of establishing KEYTRUDA as a foundational therapy, and we intend to maximize its opportunity and patient impact. In addition, we have an expanding portfolio of commercial and developmental oncology assets beyond KEYTRUDA, which offer meaningful growth opportunities beyond 2028.”

- Merck CEO Rob Davis. Q4 2021 Earnings Conference Call
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News